Ubs Group Ag Bionomics Limited Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.69 - $1.2 $17,225 - $29,956	24,964 Added 251.32%	34,897 $26,000
Q1 2024 May 13, 2024	BUY	$0.89 - $1.38 $8,547 - $13,253	9,604 Added 2919.15%	9,933 $10,000
Q4 2023 Feb 09, 2024	SELL	$1.13 - $4.46 $2,431 - $9,597	-2,152 Reduced 86.74%	329 $0
Q3 2023 Nov 09, 2023	BUY	$0.95 - $3.37 $2,356 - $8,360	2,481 New	2,481 $6,000
Q4 2022 Feb 08, 2023	BUY	$4.65 - $9.67 $3,464 - $7,204	745 Added 591.27%	871 $4,000
Q3 2022 Nov 10, 2022	BUY	$6.0 - $9.12 $420 - $638	70 Added 125.0%	126 $1,000
Q1 2022 May 16, 2022	SELL	$8.47 - $12.97 $8,249 - $12,632	-974 Reduced 94.56%	56 $0
Q4 2021 Feb 14, 2022	BUY	$12.35 - $14.73 $12,720 - $15,171	1,030 New	1,030 $13,000

2.5M

Ticker BNOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,518,620
Market Cap $33.5M
Description
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.